Kohlberg Kravis Roberts & Co. L.P. Bridge Bio Pharma, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $2.49 Billion
- Q3 2025
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 13,260,971 shares of BBIO stock, worth $880 Million. This represents 27.71% of its overall portfolio holdings.
Number of Shares
13,260,971
Previous 13,260,971
-0.0%
Holding current value
$880 Million
Previous $573 Million
20.29%
% of portfolio
27.71%
Previous 22.63%
Shares
6 transactions
Others Institutions Holding BBIO
# of Institutions
444Shares Held
185MCall Options Held
11.3MPut Options Held
1.84M-
Vanguard Group Inc Valley Forge, PA16.8MShares$1.12 Billion0.01% of portfolio
-
Viking Global Investors LP16MShares$1.06 Billion2.36% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$826 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X08.74MShares$580 Million0.22% of portfolio
-
Farallon Capital Management LLC San Francisco, CA8.19MShares$544 Million1.84% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $9.84B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...